Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030

icon1
USD 27.23 BN
MARKET SIZE, 2030
icon2
CAGR 10.7%
(2025-2030)
icon3
457
REPORT PAGES
icon4
575
MARKET TABLES

OVERVIEW

drug-discovery-services-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The drug discovery services market is projected to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, at a CAGR of 10.7%. The growth of the drug discovery services market can be attributed to the growing R&D expenditure from drug pharmaceutical and biopharmaceutical companies, the increasing R&D pipeline creating a need for increased analytical testing outsourcing, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development.

KEY TAKEAWAYS

  • By Region
    The North America drug discovery services market accounted for a 48.7% revenue share in 2024.
  • By Process
    By process, the hit-to-lead identification segment is expected to dominate the market.
  • By Type
    By type of service, the biology services segment is projected to grow at the fastest rate from 2025 to 2030.
  • By Drug Type
    By drug type, the small molecules segment is expected to dominate the market.
  • Key Players
    Companies like Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany) were identified as some of the star players in the drug discovery services market (global), given their strong market share and service footprint.
  • SMEs
    Companies like BioDuro-Sundia (US), Domainex (UK), and Bioascent Discovery Limited (UK), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders

Technological advancements, the introduction of new drug discovery techniques, the expiry of patents, and rising demand for specialized testing services among end users are expected to offer growth opportunities to players in this market. Stringent regulations governing drug discovery and animal usage are expected to restrain market growth to a certain extent. The drug discovery services market is facing challenges due to several factors, including reduced R&D budgets in the pharmaceutical sector and economic uncertainties due to the global landscape.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on customers’ business in the drug discovery services market is being reshaped by complexities in therapeutic modalities and pressure to move from target identification to candidate validation faster with higher translational confidence. Core clients—Tier-1/2 pharma, venture-backed and platform biotech companies, and leading academic/translational institutes are shifting spend from individual/silo services integrated, data-rich programs. Their imperatives primarily include compressing cycle times using automation/AI, raise hit quality with fragment + structure-enabled design, validate targets with multi-omics/CRISPR. Achieving these drives their clients’ clients—patients, payers, and regulators—toward faster entry into clinic, higher probability of success, better patient stratification and therapeutic response, quicker approvals for precision assets, and ultimately lower R&D cost per asset through smarter upstream decisions.

drug-discovery-services-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing research & development expenditure in pharma-biotech sector.
  • Growing pipeline of pharmaceutical and biopharmaceutical companies.
RESTRAINTS
Impact
Level
  • Stringent regulations.
OPPORTUNITIES
Impact
Level
  • Technological advancements and new drug discovery techniques.
  • Rising demand for specialized testing services.
CHALLENGES
Impact
Level
  • Economic uncertainties worldwide.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing research & development expenditure in pharma-biotech sector.

Pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products. Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts.

Restraint: Stringent regulations.

Securing safety and efficacy is the prime focus of regulatory authorities during drug approval. Although these approaches help ensure the quality of the products launched in the market, they substantially increase the cost of drug development and the final product. In price-sensitive emerging markets, this factor can significantly impact the uptake of a particular drug. Apart from this, various legislations that ensure the quality of the product (such as GMP) often increase manufacturing costs.

Opportunity: Technological advancements and new drug discovery techniques.

Startups are leveraging big data, AI, and machine learning to automate data processing and solve complex problems much more quickly than traditional data analysis methods. Protai (Israel) uses the technology to build an AI-driven drug discovery platform. Italian startup Netabolics is predicting the effects of new drugs by digitizing human cells. 3D-bioprinting technology is considered a powerful tool for building tissue and organ structures for drug discovery. In general, bioprinting uses a 3D printer to accurately deposit cells and biomaterials into precise geometries to create anatomically correct biological structures.

Challenge: Economic uncertainties worldwide.

Throughout 2023 and 2024, drug discovery services experienced a downturn due to funding cuts in pharmaceutical R&D and economic uncertainties. Drug discovery services market continuing to face the economic uncertainties worldwide, owing to impacts on funding, operations, and workforce stability. For example, global inflation has caused the prices of raw materials and laboratory equipment to ascend, exhausting already tight budgets for small biotechnology companies.

drug-discovery-services-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Multi-target endometriosis discovery alliance leading to multiple clinical candidates (Phase I). Joint early-discovery collaboration where both parties contributed targets and Evotec provided platform capabilities (HTS, medicinal chemistry, biology, DMPK) to generate first-/best-in-class non-hormonal candidates. De-risked early pipeline with multiple clinical entries; access to an integrated CRO platform for target ID → preclinical candidate; accelerates progress in a complex indication (endometriosis).
DEL-based hit discovery collaboration (and HitGen). HitGen applies its DNA-Encoded Library platform (hundreds of billions of compounds) to find novel small-molecule leads for Gilead; a separate deal licensed DEL-identified series to Kaken for development Rapid hit identification from extremely large chemical space; partner-ready IP that can be licensed/advanced; efficient starting points for difficult targets.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The drug discovery services market operates within a complex ecosystem. Many interconnected stakeholders play an important role in each new drug discovery process. This ecosystem includes suppliers of raw materials, service providers, end users, and regulatory bodies working together to ensure the successful discovery of safe and effective drugs. The market includes various types of academic institutions that conduct early-phase research to aid drug commercialization for drug companies. Regulatory bodies, along with CROs, help to ensure that the process follows security and efficacy standards.

drug-discovery-services-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

drug-discovery-services-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Drug Discovery Services Market, By Process

As of 2024, hit-to-lead identification segment held the largest share of the drug discovery services market and will continue leading the market through 2030. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process. Many CROs offer these services to pharmaceutical companies.

Drug Discovery Services Market, By Type

In 2024, biology services segment is expected to grow at the fastest pace during the forecast period. The growth of biology services can be attributed to the advancements in molecular biology and genomics, increasing demand for biologics and targeted therapies, rising R&D investments in the pharmaceutical and biotechnology sectors.

Drug Discovery Services Market, By Drug Type

The small molecules segment is expected to dominate the drug discovery services market through the forecast period. The process of small molecule drug discovery is complex and challenging. Typically, the workflow begins with initial target identification and validation through assay development, high-throughput screening, hit identification, and lead optimization to preclinical candidate selection. High-throughput screening of drug candidates plays an essential role in drug discovery.

Drug Discovery Services Market, By Therapeutic Area

The monoclonal antibodies segment is expected to dominate the antibody discovery services market through 2025 to 2030. The increase in demand for outsourcing the discovery process in this space is attributed to the rapid expansion of next-generation mAbs, including humanized, fully human, and Fc-engineered formats. Additionally, expanding the clinical pipeline of mAbs across oncology, immunology, and infectious diseases has rendered this segment with the highest growth rate .

Drug Discovery Services Market, By End User

As of 2024, the pharmaceutical & biotechnology companies segment dominated the drug discovery services market. This is attributed to the increased outsourcing of early-phase development and clinical testing services. These companies prefer to outsource research activities to boost profit margins, avoid high capital expenditures, and reduce the time required to validate the process and product.

REGION

Asia Pacific to be the fastest growing region in the drug discovery services market during forecast period

Asia Pacific is expected to grow at the fastest pace throughout the forecast period. Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to the expanding pharmaceutical & biopharmaceutical industry, rising number of CROs, implementation of favorable government policies, increasing number of newly established R&D and manufacturing facilities, and the presence of less-stringent regulations for drug discovery processes (especially in terms of using animals for research) in several APAC countries.

drug-discovery-services-market Region

drug-discovery-services-market: COMPANY EVALUATION MATRIX

In the drug discovery services key players market matrix, Labcorp (Star) leads with a strong market share and extensive service footprint, supported by its expansive global footprint and ongoing investments in integrated discovery-to-manufacturing platforms. EVOTEC (Emerging Leader) is gaining visibility with its specialized solutions and tailored solutions for antibody discovery. The company's expanding its regional presence and caters to a comprehensive portfolio of service offerings around biology and chemistry services.

drug-discovery-services-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 14.89 Billion
Market Forecast in 2030 (Value) USD 27.23 Billion
Growth Rate CAGR of 10.7% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Process:
    • Target Selection
    • Target Validation
    • Hit-to-lead identification
    • Lead Optimization
    • Candidate Validation
  • By Type:
    • Chemistry Services
    • Biology Services
  • By Drug Type:
    • Small molecules
    • Biologics
  • By Therapeutic Area:
    • Oncology
    • Infectious Diseases
    • Cardiovascular Diseases
    • Neurological Diseases
    • Immunological Diseases
    • Digestive & Gastrointestinal Diseases
    • Genitourinary & Women’s Health
    • Respiratory Diseases
    • Endocrine & Metabolic Diseases
    • Other Therapeutic Areas
  • By End User:
    • Pharmaceutical & Biotechnology companies
    • Academic & Research institutes
    • Other End Users
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East, and Africa

WHAT IS IN IT FOR YOU: drug-discovery-services-market REPORT CONTENT GUIDE

drug-discovery-services-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Landscape Analysis Additional profiles of regional/local players, their market position/share, strategies, and service portfolios Insights to uncover market gaps and refine differentiation strategies.
End User Market Assessment Comprehensive list of end users typically engaged in discovery, development & manufacturing of biologics (cell therapy, gene therapy) across targeted regions/countries. Insights on identifying potential customers of drug discovery services
Cross-segmental Analysis Cross-segmental analysis between small molecule drug discovery and type of services such as chemistry and biology services. Insights on White Spaces & Unmet Needs, interconnections and supply chain opportunities.

RECENT DEVELOPMENTS

  • January 2025 : Charles River Laboratories partnered with NJ Bio, Inc., a contract research organization specializing in integrated chemistry and bioconjugation services, to expedite clients’ antibody drug conjugate (ADC) development from concept to clinic. The strategic alliance combines Charles River’s end-to-end ADC discovery services with NJ Bio’s bioconjugation and manufacturing capabilities.
  • April 2024 : Aurigene Pharmaceutical Services Ltd. has introduced Aurigene.AI, an artificial intelligence (AI) and machine learning (ML)-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
  • November 2023 : Frontage Holdings Corporation has announced an initiative to form Global Drug Discovery Services within the organization. Global Drug Discovery Services will unify all chemistry, biology, ADME/PK operations, and pharmacology at various subsidiaries.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
41
RESEARCH METHODOLOGY
46
EXECUTIVE SUMMARY
58
PREMIUM INSIGHTS
63
MARKET OVERVIEW
Unpacking the Market Dynamics, Trends, and Regulatory Landscape Shaping the Future of Drug Discovery Services Market
66
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Booming research & development expenditure in pharma-biotech sector
    - Growing pipeline of pharmaceutical and biopharmaceutical companies
    - Rising research on rare diseases and orphan drugs
    - Increasing reliance on outsourcing due to costly in-house drug development
    RESTRAINTS
    - Stringent regulations
    OPPORTUNITIES
    - Technological advancements and new drug discovery techniques
    - Rising demand for specialized testing services
    - Patent expiry of key biologics
    - High growth prospects in emerging markets
    CHALLENGES
    - Economic uncertainties worldwide
    MARKET TRENDS
    - Adoption of AI in drug discovery
    - Increased outsourcing in emerging economies
    - Consolidation of contract research organizations
    - Integrated end-to-end R&D service offerings
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
    INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - High-throughput screening
    - CRISPR gene editing
    - Structure-based drug design/Computer-aided drug design
    COMPLEMENTARY TECHNOLOGIES
    - Automated liquid handling
    - In silico modeling
    - Patient-derived xenografts and organoids
    ADJACENT TECHNOLOGIES
    - Nanotechnology
    - Synthetic biology
    - Organ-on-a-chip technology
  • 5.10 PATENT ANALYSIS
  • 5.11 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA, BY END USER
  • 5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
    AI USE CASES
    FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET
DRUG DISCOVERY SERVICES MARKET, BY PROCESS
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By Process (Value USD Million)
113
  • 6.1 INTRODUCTION
  • 6.2 TARGET SELECTION
    INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
  • 6.3 TARGET VALIDATION
    INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
  • 6.4 HIT-TO-LEAD IDENTIFICATION
    RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
  • 6.5 LEAD OPTIMIZATION
    NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
  • 6.6 CANDIDATE VALIDATION
    GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET
DRUG DISCOVERY SERVICES MARKET, BY TYPE
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By Types (Value USD Million)
132
  • 7.1 INTRODUCTION
  • 7.2 CHEMISTRY SERVICES
    SYNTHETIC CHEMISTRY SERVICES
    - Increasing reliance on novel and efficient synthetic routes to augment growth
    ANALYTICAL CHEMISTRY SERVICES
    - Rising demand for high-quality, safe, and effective drugs to support growth
    OTHER CHEMISTRY SERVICES
  • 7.3 BIOLOGY SERVICES
    IN VITRO PROFILING SERVICES
    - Need for higher project productivity to speed up growth
    TOXICOLOGY SERVICES
    - Growing emphasis on assessing safety profiles of new drug candidates to propel market
    OTHER BIOLOGY SERVICES
DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By Drug Types (Value USD Million)
159
  • 8.1 INTRODUCTION
  • 8.2 SMALL MOLECULES
    INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
  • 8.3 BIOLOGICS
    GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET
DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By Therapeutic Area (Value USD Million)
168
  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
    GROWING INCIDENCE OF CANCER TO PROPEL MARKET
  • 9.3 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
  • 9.4 CARDIOVASCULAR DISEASES
    HIGH MORTALITY RATES TO SPUR GROWTH
  • 9.5 NEUROLOGICAL DISEASES
    INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
  • 9.6 IMMUNOLOGICAL DISORDERS
    GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
  • 9.7 ENDOCRINE & METABOLIC DISORDERS
    BOOMING DIABETIC POPULATION TO AID GROWTH
  • 9.8 RESPIRATORY DISORDERS
    RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
  • 9.9 DIGESTIVE SYSTEM DISEASES
    CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
  • 9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH
    RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
  • 9.11 OTHER THERAPEUTIC AREAS
DRUG DISCOVERY SERVICES MARKET, BY END USER
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By End User (Value USD Million)
204
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    TIER 1 COMPANIES
    - Rising research & development activities to sustain growth
    TIER 2 COMPANIES
    - Growing focus on specific therapeutic areas to drive market
    TIER 3 COMPANIES
    - Increasing specialized drug discovery projects to expedite growth
  • 10.3 ACADEMIC INSTITUTES
    INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
  • 10.4 OTHER END USERS
DRUG DISCOVERY SERVICES MARKET, BY REGION
Detailed Breakdown of Market Shares (2024) and Growth (2025-2030) for Drug Discovery Services Market, By Region and Country (Value USD Million)
224
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK OF NORTH AMERICA
    US
    - Global leadership in pharmaceutical and biopharmaceutical research to aid growth
    CANADA
    - Increasing initiatives for commercializing drugs to stimulate growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK OF EUROPE
    GERMANY
    - Rising dominance of contract research organizations to encourage growth
    UK
    - Increasing government-private sector collaborations to boost market
    FRANCE
    - Growing number of oncology research projects to propel market
    ITALY
    - High number of clinical trials and low drug approval time to promote growth
    SPAIN
    - Rising elderly population to intensify growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK OF ASIA PACIFIC
    CHINA
    - Booming pharmaceutical industry to sustain growth
    JAPAN
    - Increasing geriatric population to support growth
    INDIA
    - Growing foreign direct investments to drive market
    SOUTH KOREA
    - Favorable government support to accelerate growth
    AUSTRALIA
    - Rising number of clinical trials to foster growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK OF LATIN AMERICA
    BRAZIL
    - Reduced timeline for drug approvals to favor growth
    MEXICO
    - Favorable government policies to intensify growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Saudi Arabia
    - UAE
    - Other GCC Countries
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
Strategic Analysis of Leading Players, Market Share Analysis (%), Revenue Analysis (USD Million) & Competitive Positioning Matrix
340
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
  • 12.3 REVENUE ANALYSIS, 2020−2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/SERVICE COMPARISON
    THERMO FISHER SCIENTIFIC INC. (US)
    CHARLES RIVER LABORATORIES (US)
    LABCORP (US)
    WUXI APPTEC (CHINA)
    PHARMARON (CHINA)
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Process footprint
    - Type footprint
    - Therapeutic area footprint
    - Drug type footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    SERVICE LAUNCHES
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
In-Depth Profiles of Key Players and SMEs/Start-ups with Business Overview, Financials, Service Offerings, Recent Developments
367
  • 13.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    CHARLES RIVER LABORATORIES
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI APPTEC
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    PHARMARON
    - Business overview
    - Services offered
    - MnM view
    LABCORP
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    EVOTEC
    - Business overview
    - Services offered
    - Recent developments
    SYNGENE INTERNATIONAL LIMITED
    - Business overview
    - Services offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Services offered
    - Recent developments
    JUBILANT PHARMOVA LIMITED
    - Business overview
    - Services offered
    - Recent developments
    GENSCRIPT
    - Business overview
    - Services offered
    - Recent developments
    FRONTAGE HOLDINGS CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    PIRAMAL ENTERPRISES LTD.
    - Business overview
    - Services offered
    - Recent developments
    AURIGENE PHARMACEUTICAL SERVICES LTD.
    - Business overview
    - Services offered
    - Recent developments
    CURIA GLOBAL, INC.
    - Business overview
    - Services offered
    - Recent developments
    SHANGHAI MEDICILON INC.
    - Business overview
    - Services offered
    - Recent developments
    SYGNATURE DISCOVERY
    - Business overview
    - Services offered
  • 13.2 OTHER PLAYERS
    SELVITA
    VIVA BIOTECH
    TCG LIFESCIENCES PVT. LTD.
    SHANGHAI CHEMPARTNER
    DOMAINEX
    NUVISAN GMBH
    DALTON PHARMA SERVICES
    ARAGEN LIFE SCIENCES LTD.
    ONCODESIGN SERVICES
APPENDIX
442
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 DRUG DISCOVERY SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS
  • TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 US: BIOLOGICS GOING OFF PATENT, 2025–2030
  • TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021–2024
  • TABLE 7 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
  • TABLE 8 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
  • TABLE 9 DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025
  • TABLE 11 DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024
  • TABLE 12 DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 19 KEY BUYING CRITERIA, BY END USER
  • TABLE 20 KEY COMPANIES IMPLEMENTING AI
  • TABLE 21 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 23 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 24 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 28 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 30 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 34 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 35 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 42 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 48 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 49 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 55 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 56 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 58 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 59 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 65 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 EUROPE: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 70 LATIN AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 MIDDLE EAST: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 72 GCC COUNTRIES: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 EUROPE: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 LATIN AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 MIDDLE EAST: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 79 GCC COUNTRIES: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 82 EUROPE: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 MIDDLE EAST: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 86 GCC COUNTRIES: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 88 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 92 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 97 EUROPE: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 101 GCC COUNTRIES: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 103 NORTH AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 104 EUROPE: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 107 MIDDLE EAST: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 108 GCC COUNTRIES: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 110 NORTH AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 111 EUROPE: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 113 LATIN AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 114 MIDDLE EAST: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 115 GCC COUNTRIES: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 116 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 117 DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 121 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 122 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 123 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 124 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 125 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 126 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 128 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 129 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 130 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 132 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2024
  • TABLE 133 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 137 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 138 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 139 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 140 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 142 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 144 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 145 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 146 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 147 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES, 2024
  • TABLE 148 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 150 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 153 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 154 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 155 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS, 2024
  • TABLE 156 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 158 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 160 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 161 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 162 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 163 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2024
  • TABLE 164 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 166 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 171 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 175 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 178 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2024
  • TABLE 179 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 181 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 183 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 184 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 186 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 187 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 188 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 190 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 191 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 193 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 194 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 195 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 196 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 197 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 198 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 199 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 200 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 201 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 202 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 204 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 205 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 206 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 207 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 208 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 209 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 210 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 212 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 213 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 214 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 215 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 216 TOP REVENUE-GENERATING PHARMA COMPANIES, 2023
  • TABLE 217 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 219 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 221 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 222 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 223 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 224 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 225 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 226 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 228 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 229 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 230 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 231 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 232 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 233 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 235 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 236 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 237 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 238 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 239 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 240 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 243 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 244 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 245 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 246 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 247 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 251 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 252 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 253 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 254 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 255 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 256 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 257 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 258 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 259 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 260 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 261 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 262 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
  • TABLE 263 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 264 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 265 US: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 266 US: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 267 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 268 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 269 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 270 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 271 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 272 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 273 CANADA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 274 CANADA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 276 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 277 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 278 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 279 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 280 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 281 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 282 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 283 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 284 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 285 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 286 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 287 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 288 KEY MACROECONOMIC INDICATORS OF EUROPE
  • TABLE 289 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 290 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 291 GERMANY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 292 GERMANY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 293 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 294 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 295 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 296 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 297 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 298 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 299 UK: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 300 UK: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 301 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 302 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 303 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 304 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 305 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 306 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 307 FRANCE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 308 FRANCE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 309 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 310 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 311 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 312 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 313 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 314 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 315 ITALY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 316 ITALY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 317 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 318 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 319 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 320 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 321 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 322 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 323 SPAIN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 324 SPAIN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 325 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 326 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 327 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 328 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 329 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 330 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 331 REST OF EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 332 REST OF EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 333 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 334 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 335 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 336 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 337 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 338 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 340 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 341 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 343 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 344 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 346 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
  • TABLE 347 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 348 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 349 CHINA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 350 CHINA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 351 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 352 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 353 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 354 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 355 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 356 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 357 JAPAN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 358 JAPAN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 359 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 360 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 361 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 362 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 363 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 364 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 365 INDIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 366 INDIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 367 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 368 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 369 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 370 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 371 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 372 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 373 SOUTH KOREA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 374 SOUTH KOREA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 375 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 376 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 377 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 378 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 379 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 380 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 381 AUSTRALIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 382 AUSTRALIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 383 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 384 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 385 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 386 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 387 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 388 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 389 REST OF ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 390 REST OF ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 391 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 392 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 393 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 394 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 395 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 396 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 397 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 398 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 399 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 400 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 401 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 402 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 403 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 404 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
  • TABLE 405 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 406 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 407 BRAZIL: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 408 BRAZIL: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 409 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 410 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 411 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 412 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 413 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 414 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 415 MEXICO: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 416 MEXICO: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 417 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 418 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 419 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 420 MEXICO: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 421 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 422 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 423 REST OF LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 424 REST OF LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 425 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 426 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 427 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 428 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 429 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 430 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 431 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 432 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 433 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 434 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 435 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 436 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 437 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 438 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
  • TABLE 439 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 440 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 441 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 442 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 443 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 444 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 445 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 446 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 447 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 448 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 449 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 450 SAUDI ARABIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 451 SAUDI ARABIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 452 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 453 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 454 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 455 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 456 UAE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 457 UAE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 458 UAE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 459 UAE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 460 UAE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 461 UAE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 462 UAE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 463 UAE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 464 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 465 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 466 OTHER GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 467 OTHER GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 468 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 469 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 470 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 471 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 472 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 473 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 474 REST OF MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 475 REST OF MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 476 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 477 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 478 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 479 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 480 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
  • TABLE 481 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 482 AFRICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 483 AFRICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 484 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
  • TABLE 485 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 486 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 487 AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 488 KEY MACROECONOMIC INDICATORS OF AFRICA
  • TABLE 489 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021−2024
  • TABLE 490 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
  • TABLE 491 DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT
  • TABLE 492 DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT
  • TABLE 493 DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT
  • TABLE 494 DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 495 DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT
  • TABLE 496 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 497 DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 498 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 499 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 500 DRUG DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 501 DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 502 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 503 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
  • TABLE 504 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 505 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 506 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 507 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 508 CHARLES RIVER LABORATORIES: SERVICES OFFERED
  • TABLE 509 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES,JANUARY 2021–JANUARY 2025
  • TABLE 510 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 511 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 512 WUXI APPTEC: SERVICES OFFERED
  • TABLE 513 WUXI APPTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 514 PHARMARON: COMPANY OVERVIEW
  • TABLE 515 PHARMARON: SERVICES OFFERED
  • TABLE 516 PHARMARON: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 517 LABCORP: COMPANY OVERVIEW
  • TABLE 518 LABCORP: SERVICES OFFERED
  • TABLE 519 LABCORP: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 520 LABCORP: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 521 EVOTEC: COMPANY OVERVIEW
  • TABLE 522 EVOTEC: SERVICES OFFERED
  • TABLE 523 EVOTEC: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 524 EVOTEC: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 525 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 526 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 527 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
  • TABLE 528 SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 529 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 530 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 531 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 532 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 533 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 534 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 535 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW
  • TABLE 536 JUBILANT PHARMOVA LIMITED: SERVICES OFFERED
  • TABLE 537 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 538 JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 539 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 540 GENSCRIPT: SERVICES OFFERED
  • TABLE 541 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 542 GENSCRIPT: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 543 FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 544 FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED
  • TABLE 545 FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES,JANUARY 2021–JANUARY 2025
  • TABLE 546 FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 547 FRONTAGE HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 548 PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW
  • TABLE 549 PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED
  • TABLE 550 PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 551 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 552 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
  • TABLE 553 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 554 AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 555 AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 556 CURIA GLOBAL, INC.: COMPANY OVERVIEW
  • TABLE 557 CURIA GLOBAL, INC.: SERVICES OFFERED
  • TABLE 558 CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 559 CURIA GLOBAL, INC.: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 560 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 561 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW
  • TABLE 562 SHANGHAI MEDICILON INC.: SERVICES OFFERED
  • TABLE 563 SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 564 SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 565 SYGNATURE DISCOVERY: COMPANY OVERVIEW
  • TABLE 566 SYGNATURE DISCOVERY: SERVICES OFFERED
  • TABLE 567 SYGNATURE DISCOVERY: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 568 SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 569 SELVITA: COMPANY OVERVIEW
  • TABLE 570 VIVA BIOTECH: COMPANY OVERVIEW
  • TABLE 571 TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
  • TABLE 572 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
  • TABLE 573 DOMAINEX: COMPANY OVERVIEW
  • TABLE 574 NUVISAN GMBH: COMPANY OVERVIEW
  • TABLE 575 DALTON PHARMA SERVICES: COMPANY OVERVIEW
  • TABLE 576 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
  • TABLE 577 ONCODESIGN SERVICES: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 DRUG DISCOVERY SERVICES MARKET: YEARS CONSIDERED
  • FIGURE 3 DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 5 GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION, 2024
  • FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
  • FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
  • FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 DRUG DISCOVERY SERVICES MARKET: CAGR PROJECTIONS, 2025–2030
  • FIGURE 11 DRUG DISCOVERY SERVICES MARKET: DATA TRIANGULATION
  • FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030
  • FIGURE 16 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025–2030
  • FIGURE 18 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET
  • FIGURE 19 SMALL MOLECULES SEGMENT AND US LED NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2024
  • FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
  • FIGURE 22 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 GLOBAL PHARMACEUTICAL R&D SPENDING, 2016–2030
  • FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2014–2024
  • FIGURE 25 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013–2023
  • FIGURE 26 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013–2023 (USD BILLION)
  • FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET
  • FIGURE 28 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
  • FIGURE 29 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
  • FIGURE 30 DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 31 DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 32 DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 33 INVESTMENT AND FUNDING SCENARIO, 2022–2025
  • FIGURE 34 DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014–2024
  • FIGURE 35 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 37 KEY BUYING CRITERIA, BY END USER
  • FIGURE 38 AI USE CASES
  • FIGURE 39 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)
  • FIGURE 40 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
  • FIGURE 41 DISTRIBUTION OF PHARMACEUTICAL R&D COMPANIES, BY COUNTRY/REGION, 2023 VS. 2024
  • FIGURE 42 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
  • FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020−2024
  • FIGURE 44 MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024
  • FIGURE 45 RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024
  • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 47 EV/EBITDA OF KEY PLAYERS, 2024
  • FIGURE 48 DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARISON
  • FIGURE 49 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 50 DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 51 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 54 WUXI APPTEC: COMPANY SNAPSHOT (2023)
  • FIGURE 55 PHARMARON: COMPANY SNAPSHOT (2023)
  • FIGURE 56 LABCORP: COMPANY SNAPSHOT (2023)
  • FIGURE 57 EVOTEC: COMPANY SNAPSHOT (2023)
  • FIGURE 58 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023)
  • FIGURE 59 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 60 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023)
  • FIGURE 61 GENSCRIPT: COMPANY SNAPSHOT (2023)
  • FIGURE 62 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 63 PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 64 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)

Methodology

The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery services market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery services market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery services market, which was further validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery services market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Drug Discovery Services Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Drug Discovery Services Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies.

Stakeholders

  • Drug discovery service providers
  • Pharmaceutical and biotechnology companies
  • Academic & Research Institutes
  • Contract Research Organization
  • Market Research and Consulting Firms
  • R&D Centers
  • Researchers and Scientists
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Industry Associations and Professional Societies

Report Objectives

  • To define, describe, and forecast the drug discovery services market by value by process, type, drug type, therapeutic area, end user and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery services market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

 

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Drug Discovery Services Market

DMCA.com Protection Status